Ebola-Associated Genes in the Human Genome: Implications for Novel Targets

2015

Self Cite

Section: Discussionmentioning

confidence: 99%

“…The bioinformatics and proteomics tools used in the study have been described. [35][36][37] The GWAS catalogue 38 and the NCBI Phenome-Genome Integrator, PheGenI 39 were used to create a working list of VAG. Characterization of the VAG was performed using the GeneALaCart, GeneAnalytics and VarElect data mining tools from the GeneCards.…”

Section: Methodsmentioning

confidence: 99%

Druggable Vitiligo Genome: A Fast Track Approach to Take the Genome Wide Association to the Clinic

2015

Self Cite

“…In series of recent studies, various FDA-approved drugs were identified for repurposing for the treatment of the Ebola hemorrhagic fever. [32][33][34] The protein similarity of the Zika-related viruses suggests that common molecular targets may exist in the host genome. 16,17,[35][36][37] Hence, efforts were undertaken to identify molecular targets for the Zika-related viruses.…”

Section: February 2016) the Us Center For Disease Control (Cdc) Recementioning

confidence: 99%

Zika virus Therapeutics: Drug Targets and Repurposing Medicine from the Human Genome

2016

Self Cite

Zika viral infection is caused by an emerging mosquito-borne virus, the Zika virus (ZIKV) and threatens to become a global pandemic. While not life threatening, the Zika Virus Disease (ZVD) is suspected to be associated with severe neurological disorders including Guillain-Barré syndrome and microcephaly. Currently, no known cure or diagnostic tests for ZVD are available. The host cell molecular targets are unknown for ZIKV. The ZIKV is related to various other mosquito borne viruses including the Chikungunya, Dengue, Japanese encephalitis, Spondweni, Yellow fever and West Nile viruses. The host cell targets are known for most of these viruses. All of these viruses harbor common protein motifs and domains, raising the possibility of shared molecular targets in the host genome. To facilitate target(s) discovery for the ZIKV therapy, the disease-and protein-knowledge databases were datamined for Zika-related viruses. An initial database of 251 genes was established. Additional filtering using variants associated with the Zika-related viruses and neurological disease phenotypes, identified 55 putative candidate ZIKV targets. These encompass druggable proteins including adhesion molecules, chemokines, enzymes, interleukins, receptors and transporters. Genes linked to Guillain-Barré syndrome and microcephaly was among the Zika candidate genes. The protein expression of the candidate genes was detected in diverse body fluids. Drug bank datamining of these candidate targets identified seventy-nine FDA-approved drugs of the class antineoplastics, anti diabetic, anti-inflammatory, antivirals, antibiotics, statins and neutraceuticals. The database of genes from the study provides a framework for diagnosis and therapy of the ZVD. The FDA-approved list of drugs, if verified, may offer a repurposing use for the treatment of the ZVD.

show abstract

“…6 Reasoning that the uncharacterized proteins may offer new opportunities for therapeutic intervention, we have embarked on a systematic characterization of the Open Reading Frames (ORFs) present in the human genome. [7][8][9][10][11] The Genetic Association Database (GAD) provided a starting point to identify disease relevant ORFs of the dark Matter proteome. 12 The ORF hits from the GAD were complemented with other disease-oriented databases including the MalaCards 13 and the NextBio Meta analysis tool.…”

Section: Introductionmentioning

confidence: 99%

Atlas of the Open Reading Frames in Human Diseases: Dark Matter of the Human Genome

2015

Self Cite